Lupirtin-SR Tablet contains Flupirtine 400 mg, a centrally acting non-opioid analgesic with muscle-relaxant properties, indicated for the management of moderate to severe acute and chronic pain. Flupirtine exerts its analgesic effect primarily through selective neuronal potassium channel opening and indirect NMDA receptor antagonism, resulting in membrane hyperpolarization and reduced neuronal excitability. This mechanism provides effective pain relief without the typical side effects associated with opioid analgesics, such as respiratory depression or dependence. Lupirtin-SR is commonly prescribed for conditions including musculoskeletal pain, neuropathic pain, postoperative pain, and migraine. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, allowing for convenient dosing and improved patient compliance. It is contraindicated in patients with liver impairment, porphyria, or hypersensitivity to flupirtine. Caution is advised in patients with hepatic dysfunction due to the risk of hepatotoxicity; regular monitoring of liver function tests is recommended during prolonged therapy. Common adverse effects may include dizziness, nausea, and fatigue. Lupirtin-SR should be used under medical supervision, adhering strictly to prescribed dosages to minimize potential risks. It is not recommended for use in pediatric populations or during pregnancy and lactation unless clearly indicated by a healthcare professional.